ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · USD

$20.3

+0.13 (+0.6%)· Recorded snapshot

Market cap	3.5B
Revenue (ttm)	1.1B
Net income (ttm)	380.5M
EPS (ttm)	$2.21
Shares out	172.3M
P/E (trailing)	9.2x
P/E (forward)	25.8x
Volume	962,940
Beta	0.89

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.1B
Net income (ttm): 380.5M
EPS (ttm): $2.21
P/E (trailing): 9.2x
P/E (forward): 25.8x
Market cap: 3.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E25.8

P25 n/aP50 n/aP75 n/a

Trailing P/E9.2

P25 n/aP50 n/aP75 n/a

ROE35.7

P25 n/aP50 n/aP75 n/a

ROIC19.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ACAD indicators

Market & fundamental data

Available fields

255

Groups with data

Currency

USD

Showing 255 of 255 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001070494
Company name	ACADIA Pharmaceuticals Inc.
Country	United States
Country code	US
CUSIP number	004225108
Earnings date	2026-11-04
Earnings time	amc
Employees	798
Employees change	144
Employees growth	22.02%
Enterprise value	$2.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1993
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2004-05-27
Is primary listing	Yes
Is SPAC	No
ISIN number	US0042251084
Last 10-K release date	2026-02-26
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$20.30
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ACAD
U.S. state	California
Website	https://acadia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	26.8x
Average P/E ratio (3Y)	21.82x
Earnings yield	10.87%
EV/Earnings	6.86x
EV/EBIT	30.24x
EV/EBITDA	26.54x
EV/FCF	17.93x
EV/Sales	2.29x
FCF / EV yield	5.58%
FCF yield	4.17%
Forward EV/Sales	1.86x
Forward P/E	25.79x
Forward P/S	2.49x
Graham number	19.40991
Graham upside	-4.29%
P/(FCF - SBC) ratio	39.9x
P/(OCF - SBC) ratio	34.17x
P/B ratio	2.66x
P/E ratio	9.2x
P/FCF ratio	24x
P/OCF ratio	21.8x
P/S ratio	3.07x
Price / tangible book value	2.9x
Price/EBITDA ratio	35.51x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	7.59%
EBITDA margin	8.64%
FCF margin	12.79%
Gross margin	62.06%
Operating margin	7.59%
Pretax margin	10.66%
Profit margin	33.42%
Profit per employee	$476,797
Profitable quarters	11
Profitable years	2
Revenue per employee	$1.4M
ROA	3.64%
ROA (5Y)	-6.55%
ROCE	6.25%
ROE	35.74%
ROE (5Y)	-2.12%
ROIC	19.82%
SBC / revenue	5.1%
Tax / revenue	-22.76%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	66.4%
EPS growth (Q)	13.29%
EPS growth (QoQ)	800%
EPS growth quarters	1
EPS growth years	3
FCF growth	-22.16%
FCF growth (Q)	50.32%
FCF growth (QoQ)	232.62%
Gross profit growth	15.18%
Gross profit growth (Q)	19.42%
Gross profit growth 3Y	40.97%
Gross profit growth 5Y	28.71%
Net income growth	71.27%
Net income growth (Q)	18.13%
Net income growth (QoQ)	766.1%
Net income growth quarters	1
Net income growth years	3
OCF growth	-14.68%
OCF growth (Q)	57.58%
OCF growth (QoQ)	196.58%
Operating income growth	-4.35%
Operating income growth (Q)	16.87%
Revenue growth	11.75%
Revenue growth (Q)	16.4%
Revenue growth (QoQ)	14.88%
Revenue growth 10Y	143.25%
Revenue growth 3Y	27.38%
Revenue growth 5Y	19.7%
Revenue growth quarters	15
Revenue growth years	10

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-14.7M
Depreciation and amortization	$12M
EBIT	$86.4M
EBITDA	$98.4M
EPS	$2.21
FCF per share	$0.85
Financing cash flow	$46.8M
Free cash flow	$145.6M
Free cash flow minus SBC	$87.6M
Gross profit	$706.7M
Income taxes	$-259.1M
Investing cash flow	$-77.5M
Net cash flow	$129.7M
Net income	$380.5M
Operating cash flow minus SBC	$102.3M
Operating income	$86.4M
Revenue	$1.1B
Stock-based compensation	$58.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.43
Book value per share	$7.59
Debt / EBITDA	0.66
Debt / equity	0.06
Debt / FCF	0.51
Long-term assets	$518.4M
Long-term liabilities	$74.9M
Net cash (debt)	$882.6M
Net cash / market cap	25.26%
Net cash growth	25.07%
Net debt / EBITDA	-8.97
Net debt / equity	-0.68
Net debt / FCF	-6.06
Piotroski F-Score	5
Property, plant and equipment	$86.5M
Shareholders' equity	$1.3B
Tangible book value	$1.2B
Tangible book value per share	$6.99
Total assets	$1.7B
Total cash	$956.5M
Total debt	$73.9M
Total liabilities	$436.3M
WACC	8.94%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.77
Current assets	$1.2B
Current liabilities	$361.4M
Current ratio	3.39
Inventory turnover	14.77
Net working capital	$-79.1M
Quick ratio	3.11
Working capital	$863.1M
Working capital turnover	1.52

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.98%
Dividend yield	0%
Shareholder yield	-2.98%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-10.55%
10Y return CAGR	-1.11%
10Y total return	-10.55%
150-day SMA	$23.75
15Y price change	1,581.67%
15Y return CAGR	20.7%
15Y total return	1,581.67%
1D price change	0.64%
1M price change	-2.42%
1M total return	-2.42%
1W price change	-1.27%
1W total return	-1.27%
1Y price change	-12.22%
1Y return CAGR	-12.23%
1Y total return	-12.22%
20-day SMA	$19.77
200-day SMA	$23.74
20Y price change	110.87%
20Y return CAGR	3.8%
20Y total return	110.87%
3M price change	-20.52%
3M total return	-20.52%
3Y price change	-7.26%
3Y return CAGR	-2.48%
3Y total return	-7.26%
50-day SMA	$24.10
50-day SMA vs 200-day SMA	50over200
52-week high	$30.96
52-week high date	2026-08-19
52-week low	$18.39
52-week low date	2026-10-13
5Y price change	14.92%
5Y return CAGR	2.82%
5Y total return	14.92%
6M price change	-9.51%
6M total return	-9.51%
All-time high	$58.72
All-time high date	2020-07-07
All-time low	$0.65
All-time low date	2010-11-12
Average true range (ATR)	$0.69
Average volume	1.7M
Beta (1Y)	0.86
Beta (2Y)	1.16
Beta (5Y)	0.89
Change from 52-week high	-34.43%
Change from 52-week low	10.39%
Change from all-time high	-65.63%
Change from all-time low	3,004.62%
Change from open	1.1%
Day's gap	-0.45%
Dollar volume	$19.5M
High price	$20.30
Low price	$20.07
Monthly RSI	46.29
Open price	$20.08
Position in 52-week range	100%
Premarket change	-0.84%
Premarket close	$20.17
Premarket price	$20.00
Previous close	$20.17
Price vs 150-day SMA	-15.04%
Price vs 20-day SMA	2.08%
Price vs 200-day SMA	-15%
Price vs 50-day SMA	-16.25%
Relative volume	0.57
RSI	41.15
Sharpe ratio	-0.25
Sharpe ratio (3Y)	0.09
Sharpe ratio (5Y)	0.25
Sortino ratio	-0.2
Sortino ratio (3Y)	0.27
Sortino ratio (5Y)	0.48
Volume	962.9K
Weekly RSI	38.68
YTD price change	-24.45%
YTD total return	-24.45%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	128.3M
Float percentage	74.49%
Shares change (QoQ)	0.08%
Shares change (YoY)	2.98%
Shares held by insiders	0.55%
Shares held by institutions	74.95%
Shares outstanding	172.3M
Short % of float	6.45%
Short % of shares	4.8%
Short ratio	3.9 days

Deeper analysis on ACAD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ACAD report

Is a complete ACAD research report available?

No complete published report is available for ACADIA Pharmaceuticals Inc. (ACAD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ACADIA Pharmaceuticals Inc. (ACAD)

Price

Financial snapshot

Fair-value bridge

Latest news · ACAD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ACAD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ACAD

Frequently asked questions